
Woehlk and colleagues conducted a study on sublingual allergen immunotherapy (AIT) with house dust mite (HDM) extract, shedding new light on its effects in asthma treatment. Their randomized, double-blind, placebo-controlled trial revealed that AIT increases the expression of type I and III interferons (IFNs) while decreasing IL-33 expression in the lower airways of patients. These findings suggest that AIT could potentially reduce exacerbation rates in asthma patients. The study also explored the interactions between allergen exposure, viral infection, and AIT in the airway mucosa, highlighting various mechanisms that contribute to airway damage and inflammation. Moreover, the increase in type I and III IFNs induced by AIT may have implications for the severity of COVID-19, as these IFNs are crucial in early antiviral responses. However, the relationship between COVID-19 and asthma is complex and requires further investigation. Overall, this research has the potential to challenge existing beliefs in allergy and immunology.
Like
Save
Share